ADMA Biologics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by ADMA Biologics, Inc. on October 15, 2021, reporting a corporate governance event. The Company is incorporated in Delaware and its common stock trades on the Nasdaq Global Market under the symbol "ADMA".
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on a Board of Directors appointment.
Material Changes
The primary material change reported is the appointment of Young T. Kwon, Ph.D., to the Board of Directors as a Class II director. His term is set to expire at the Company's 2024 annual meeting of stockholders.
Management Commentary and Compensation
Dr. Kwon brings significant experience from roles at Momenta Pharmaceuticals Inc. (including Chief Financial and Business Officer) and Biogen Idec. As a non-employee director, he will receive compensation in accordance with the Company's general policies. This includes an initial grant of options to purchase 93,500 shares of the Company's common stock upon joining the Board. The Company confirmed there are no undisclosed arrangements regarding his selection.
Investor Verification Checklist
- Verify the exact number of option shares granted (93,500) and the vesting schedule in the Company's 2014 Omnibus Incentive Compensation Plan.
- Review the press release dated October 18, 2021 (Exhibit 99.1) for additional biographical details on Dr. Kwon.
- Confirm the expiration date of Dr. Kwon's director term (2024 annual meeting).
- Check subsequent filings for any changes to the Board composition or executive compensation policies.